ArticleInfection and drug resistance2026
Operationalizing the WHO Blueprint for Fungal Disease and Antifungal Resistance in Fragile Health Systems: Insights from Somalia.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) Blueprint for Strengthening Responses to Fungal Disease and Antifungal Resistance provides a global framework for improving national responses to fungal diseases and antifungal resistance. However, translating these recommendations into routine practice remains challenging in fragile and resource-constrained health systems, where weak governance, limited laboratory capacity, workforce shortages, constrained financing, and fragile supply chains may hinder implementation. Using Somalia as an illustrative context, this narrative policy commentary examines how such health-system constraints may affect operationalization of the WHO Blueprint. Somalia specific evidence on fungal disease burden and antifungal resistance remains limited; therefore, the country is used as an implementation context rather than as an evaluated fungal disease program. Drawing on the WHO Blueprint, established health-system strengthening concepts, and implementation constraints relevant to fragile settings, we propose a phased approach built around five interconnected priorities: strengthening governance and coordination, expanding laboratory and surveillance capacity, ensuring sustainable access to essential antifungal medicines, developing the health workforce, and integrating fungal disease services within existing health-system platforms. Rather than establishing new vertical programs, fragile health systems should leverage existing antimicrobial-resistance initiatives, laboratory networks, procurement mechanisms, and clinical training structures to improve feasibility and sustainability. Although derived from the Somalia context, these considerations may also be relevant to other settings facing similar resource and system constraints. The success of the WHO Blueprint will ultimately depend on the ability of health systems to adapt global recommendations into feasible and sustainable national action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.